High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
复制标题
DOI：
10.1200/jco.2005.01.1825
复制
发表时间：
2005-10-01
影响因子：
45.3
通讯作者：
Cabanillas, FF
中科院分区：
文献类型：
--
作者：
Romaguera, JE;Fayad, L;Cabanillas, FF
目的：确定利妥昔单抗联合强化疗方案治疗既往未经治疗的侵袭性套细胞淋巴瘤（MCL）患者的反应、无失败生存期（FFS）、总生存率和毒性。患者和方法：这是一项利妥昔单抗联合环磷酰胺、长春新碱、阿霉素和地塞米松的前瞻性11期试验（hyper-CVAD;认为一个周期）每21天交替使用利妥昔单抗加高剂量甲氨蝶呤-阿糖胞苷（认为一个周期），总共6至8个周期。中位随访时间为40个月，3年FFS和总生存率分别为64%和82%，曲线无平台。患者亚组的
Purpose: To determine the response, failure-free survival (FFS), and overall survival rates and toxicity of rituximab plus an intense chemotherapy regimen in patients with previously untreated aggressive mantle-cell lymphoma (MCL).Patients and Methods: This was a prospective phase 11 trial of rituximab plus fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD; considered one cycle) alternating every 21 days with rituximab plus high-dose methotrexate-cytarabine (considered one cycle) for a total of six to eight cycles.Results: Of 97 assessable patients, 97% responded, and 87% achieved a complete response (CR) or unconfirmed CB. With a median follow-up time of 40 months, the 3-year FFS and overall survival rates were 64% and 82%, respectively, without a plateau in the curves. For the subgroup of patients